Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
 - EconoTimes)
NEW YORK, Feb. 21, 2018 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Tesaro, Inc. (NASDAQ:TSRO) who purchased shares between March 14, 2016 and January 12, 2018. The action, which was filed in the United States District Court for the District of Massachusetts, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that (i) substantial undisclosed health risks, including anaphylaxis and anaphylactic shock, were associated with Tesaro's intravenous formulation of VARUBI (rolapitant); and (ii) as a result of the foregoing, Tesaro's shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages. On January 12, 2018, Tesaro announced it had updated the U.S. labeling of VARUBI (rolapitant) injectable emulsion packages after reports that some patients receiving the treatment experienced “Anaphylaxis, anaphylactic shock and other serious hypersensitivity reactions.”
Shareholders have until March 19, 2018 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sb/tesaro-inc?wire=3.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
